Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both?

J AAPOS. 2012 Feb;16(1):2-4. doi: 10.1016/j.jaapos.2011.11.002. Epub 2012 Jan 10.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / adverse effects*
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Bevacizumab
  • Health Services Misuse
  • Humans
  • Infant, Newborn
  • Off-Label Use
  • Retinopathy of Prematurity / drug therapy*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab